The HART CVE blood test technology, made by Prevencio, determines a patient’s risk of a heart attack, stroke and cardiovascular death. While HART CADhs assesses whether a patient’s arteries are obstructed, according to a July 24 news release.
The platform can be used to develop diagnostics beyond cardiac diseases.
“Based on our AI-based diagnostic development expertise, Seattle Children’s Hospital and Research Institute solicited Prevencio to use our HART platform to develop and commercialize a diagnostic for Kawasaki disease, a childhood disease in which there was no commercially available diagnostic,” Prevencio CEO Rhonda Rhyne said in the release. “The company has also been engaged by leading cancer centers and global companies to use the HART platform and HART tests for assessing patient risk, efficacy of treatments, and development of diagnostics and other devices.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
